These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8073927)

  • 1. [Treatment of tumor osteopathy in cancer of the prostate].
    Alcover J; Fernández-Conde M; Carrere W; Serrallach M; Carretero P
    Actas Urol Esp; 1994 May; 18 Suppl():409-16. PubMed ID: 8073927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Physiopathology, diagnosis and management of bone metastases from prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S349-56. PubMed ID: 19070815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
    Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
    Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of metastatic bone disease and risk of skeletal morbidity.
    Coleman RE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6243s-6249s. PubMed ID: 17062708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
    Ryan CJ; Elkin EP; Cowan J; Carroll PR
    Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
    Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
    J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
    Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
    Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Incidence and nature of metastases of prostatic cancer based on autopsy data].
    Makarova GV; Gorilovskiĭ LM; Okunev DIu
    Vopr Onkol; 1987; 33(4):78-83. PubMed ID: 3590663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
    J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
    Ye L; Kynaston HG; Jiang WG
    Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer: the role of hormonal therapy.
    Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
    J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of tumor microenvironment in prostate cancer bone metastasis.
    Morrissey C; Vessella RL
    J Cell Biochem; 2007 Jul; 101(4):873-86. PubMed ID: 17387734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
    Logothetis CJ; Navone NM; Lin SH
    Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.